The median overall survival for AML patients with high BUB1B expression was ~10 months in comparision to ~19 months for patients exhibiting low expression of BUB1B; however the association was not statistically significant (HR 1.35, CI 0.88-2.05; logrank p=0.16) (Figure 4D). Here, BUB1B is linked to acute myeloid leukemia.